Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Suguru HARADA"'
Autor:
Ryohei Kawasaki, Asuka Sakata, Kohei Tatsumi, Seiji Mitani, Maiko Takeda, Shogo Kasuda, Naoki Matsumoto, Suguru Harada, Tetsuhiro Soeda, Yukiko Nishida, Yasushi Yoshimura, Midori Shima
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Arthropathy is a common complication in haemophilia and decreases quality of life. It has been known that concentrations of β-hydroxybutyrate (BHB) in blood are increased by a ketogenic diet, and elevated levels of circulating BHB restricts
Externí odkaz:
https://doaj.org/article/e4317ddda0cd4c68b9459e14c15cdd6d
Autor:
Ryohei Kawasaki, Asuka Sakata, Chihiro Hosoda, Suguru Harada, Tetsuhiro Soeda, Yukiko Nishida, Naoki Matsumoto, Kohei Tatsumi, Keiji Nogami, Yasushi Yoshimura, Midori Shima
Publikováno v:
Thrombosis Journal, Vol 21, Iss 1, Pp 1-8 (2023)
Abstract Background In patients with hemophilia (PwH), bleeding often occurs in joints and muscles, and early detection of hemorrhage is important to prevent the onset and progression of mobility impairment. Complex-Image analysis such as ultrasonogr
Externí odkaz:
https://doaj.org/article/ca06c06577a74ff18d4a4cd4f62a3558
Autor:
Naoki Matsumoto, Hiroto Abe, Ryohei Kawasaki, Yoshihito Tashiro, Mariko Noguchi-Sasaki, Suguru Harada, Koichiro Yoneyama, Tomomi Niino, Tetsuhiro Soeda, Yasushi Yoshimura
Publikováno v:
TH Open, Vol 07, Iss 03, Pp e241-e243 (2023)
Externí odkaz:
https://doaj.org/article/12ff278caee346a7a9c631bc8db8a400
Autor:
Suguru Harada, Tsukasa Tominari, Chiho Matsumoto, Michiko Hirata, Morichika Takita, Masaki Inada, Chisato Miyaura
Publikováno v:
Journal of Pharmacological Sciences, Vol 115, Iss 1, Pp 89-93 (2011)
Nobiletin, a polymethoxy flavonoid, prevents cancer and inflammation, but the roles of nobiletin in bone are unclear. We examined the effects of nobiletin on bone resorption in vitro and on bone mass in ovariectomized (OVX) mice in vivo. In vitro, no
Externí odkaz:
https://doaj.org/article/6d92688c1215413ab5962f0fde5ead71
Autor:
Suguru HARADA
Publikováno v:
EU Studies in Japan. 2021:103-121
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f0ab0aff6e59db98154e64bc9437d10
https://doi.org/10.5135/eusj.2021.103
https://doi.org/10.5135/eusj.2021.103
Autor:
Keigo Yorozu, Kaname Yamamoto, Suguru Harada, Mitsue Kurasawa, Toshiki Iwai, Masamichi Sugimoto
Publikováno v:
Oncology Reports
Vascular endothelial growth factor (VEGF)-neutralizing therapy with bevacizumab has become increasingly important for treating colorectal cancer. It was demonstrated that second-line chemotherapy together with bevacizumab after disease progression (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14392ddbebe3747336f31d753ffd0a4a
https://doi.org/10.3892/or.2016.4902
https://doi.org/10.3892/or.2016.4902
Autor:
SUGURU HARADA1, MIEKO YANAGISAWA1, SAORI KANEKO1, KEIGO YOROZU1, KANAME YAMAMOTO1, YOICHIRO MORIYA1, NAOKI HARADA1 haradanok@chugai-pharm.co.jp
Publikováno v:
Molecular & Clinical Oncology. Sep/Oct2015, Vol. 3 Issue 5, p987-994. 8p.
Publikováno v:
Anticancer research. 39(4)
Background Immune checkpoint inhibitors have marked antitumor effect. However, monotherapy benefits only a limited population of patients, and further improvement of their effects is required. Here the therapeutic effect and immune response during an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9d77772c7d63a341ac4d4cc91365c51
https://pubmed.ncbi.nlm.nih.gov/30952714
https://pubmed.ncbi.nlm.nih.gov/30952714
Autor:
Naoki Harada, Yoichiro Moriya, Suguru Harada, Keigo Yorozu, Kaname Yamamoto, Mieko Yanagisawa, Saori Kaneko
Publikováno v:
Molecular and Clinical Oncology. 3:987-994
In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3dff9bea604d3c67b2bc4f38df13ab5
https://doi.org/10.3892/mco.2015.609
https://doi.org/10.3892/mco.2015.609
Autor:
Satoshi Takeda, Suguru Harada, Toshihide Mizoguchi, Yuko Nakamichi, Yasuhiro Kobayashi, Tatsuo Suda, Hisataka Yasuda, Nobuyuki Udagawa, Hitoshi Saito, Sadaoki Sakai, Naoyuki Takahashi, Fumiaki Takahashi
Publikováno v:
Journal of Bone and Mineral Research. 27:461-473
Eldecalcitol (ED-71) is a new vitamin D₃ derivative recently approved for the treatment of osteoporosis in Japan. Previous studies have shown that the daily administration of ED-71 increases bone mineral density (BMD) by suppressing bone resorption
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07a82b6edcb99822db567aaec4004222
https://doi.org/10.1002/jbmr.555
https://doi.org/10.1002/jbmr.555